Functional outcomes of robot‐assisted partial nephrectomy in patients with a solitary kidney
BJU International · 2025-07 · 136 (1) · 55-62
DOI: 10.1111/bju.16677 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 06.03.2025. Verfasst von Nicolas A Soputro und 8 weiteren Autor:innen. Beteiligte Einrichtung: Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Robotic Surgical Procedures, Nephrectomy, Kidney Neoplasms, Solitary Kidney. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the long‐term functional outcomes of robot‐assisted partial nephrectomy (RAPN) in patients with and without a solitary kidney. Materials and Methods A retrospective review was performed using the prospectively maintained, institutional review board‐approved database to identify all consecutive patients who underwent RAPN between 2006 and 2023. A propensity‐score‐matched analysis was subsequently undertaken to compare patients with and without a solitary kidney. The analysis controlled for various baseline clinicodemographic variables, including age, comorbidities, and baseline tumour characteristics.
Results
Of the 1698 RAPN patients included in our series, 86 were identified to have a pre‐existing solitary kidney. Following a 1:1 propensity‐score‐matched comparison analysis, the solitary kidney cohort was noted to have similarly favourable long‐term functional outcomes to the cohort with bilaterally functioning kidneys. This was also indicated by our Kaplan–Meier analysis, which highlighted identical survival from kidney disease progression at a median follow‐up duration of 45 months ( P = 0.101). Improvements in functional outcomes could be observed as early as 3 months after the respective surgery (median glomerular filtration rate preservation in the solitary vs non‐solitary kidney group: 63.7% vs 64.7%; P = 0.815). Of note, the solitary kidney group was more at risk of postoperative acute kidney injury (AKI; solitary vs non‐solitary kidney group: 79.7% vs 57.7%; P < 0.001). Lower preoperative renal function (odds ratio [OR] 0.963, 95% confidence interval [CI] 0.922–0.991; P = 0.028), main artery clamping (OR 5.015, 95% CI 1.044–27.462; P = 0.027), and ischaemia time beyond 25 min (OR 4.335, 95% CI 1.381–13.846; P = 0.014) were identified as independent predictors of AKI.
Conclusion
Leveraging a large series of RAPN cases in patients with a solitary kidney, we identified similarly favourable long‐term functional outcomes between patients with a solitary kidney and those with bilaterally functioning kidneys. Notably, patients with solitary kidneys remained at increased risk of postoperative AKI. Additional vulnerability to AKI can be conferred by other variables, such as pre‐existing kidney disease and warm ischaemia time exceeding 25 min.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Zitieren
APA
Soputro, N. A., Mikesell, C. D., Younis, S. K., Rai, S., Wang, L., Ionson, A. C., Pedraza, A. M., Weight, C. J., & Kaouk, J. (2025). Functional outcomes of robot‐assisted partial nephrectomy in patients with a solitary kidney. BJU International, 136(1), 55-62. https://doi.org/10.1111/bju.16677
Vancouver
Soputro NA, Mikesell CD, Younis SK, Rai S, Wang L, Ionson AC, et al. Functional outcomes of robot‐assisted partial nephrectomy in patients with a solitary kidney. BJU International. 2025;136(1):55-62. doi:10.1111/bju.16677
BibTeX
@article{Soputro2025,
author = {Soputro, Nicolas A and Mikesell, Carter D and Younis, Salim K and Rai, Samarpit and Wang, Lin and Ionson, Annaliese C and Pedraza, Adriana M and Weight, Christopher J and Kaouk, Jihad},
title = {Functional outcomes of robot‐assisted partial nephrectomy in patients with a solitary kidney},
journal = {BJU International},
year = {2025},
volume = {136},
number = {1},
pages = {55--62},
doi = {10.1111/bju.16677}
}
EUVIMED